Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control throughout protocol treatment
Female participants of childbearing potential must adhere to using a medically accepted method of birth control up to  days prior to screening and agree to continue its use during the study or be surgically sterilized (e.g., hysterectomy or tubal ligation) and males must agree to use barrier methods of birth control while on study; WOCBP must agree to use effective contraception during treatment and for at least  months following the last dose of study treatment
Women of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to  months following treatment
Fertile men must agree to use an effective method of birth control during the study and for up to  months after the last dose of study drug.
Women of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to  months following treatment
Fertile men must agree to use an effective method of birth control during the study and for up to  months after the last dose of study drug
Men and women of childbearing potential must be willing to practice an effective method of birth control during treatment and at least  months after treatment is finished
Women of childbearing potential who are sexually active and are not willing to use a highly effective method of birth control during the study period
Women of childbearing potential are willing to agree to use  of the study-defined effective methods of birth control from the time of study entry to  months after the last day of treatment
Male patients with female partners of childbearing potential, and female patients of childbearing potential must agree to use effective birth control. Effective birth control and cessation of lactation must be complied at least  weeks prior to first study drug administration, during the trial participation, and for  months after the last dose of study drug
Men and women of reproductive potential who are unwilling to practice a highly effective method(s) of birth control while on study through  week (women) or  weeks (men)
Women of childbearing potential are willing to agree to use  of the study defined effective methods of birth control from the time of study entry to  months after the last day of treatment
Inability or refusal to practice effective contraception during therapy; men and women of childbearing potential must use an effective method of birth control or abstinence during treatment and for  months after completion of the treatment
Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months after completion of treatment
Women of childbearing potential (WCBP) must agree to use highly effective methods of birth control throughout the duration of the study until  months following the last dose of study drug.
Not willing to use an effective method of birth control
Fertile men must agree to use an effective method of birth control during the study and for up to  months after the last dose of study drug.
Men and women of childbearing potential must practice birth control; women of child bearing potential must have a urine pregnancy test within  days of study entry; in accordance with topotecan hydrochloride (topotecan) administration guidelines, women must practice birth control for at least  month following chemotherapy infusion; men must practice birth control for at least four months following termination of chemotherapy infusion
Men and women of childbearing potential must be willing to exercise an effective form of birth control (abstinence/contraception) while on study and for  months after therapy completed
Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control
Women of childbearing potential and male participants must agree to use a medically effective means of birth control throughout their participation in the treatment phase of the study and until  months following the last study treatment.
Women of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to  months following treatment
Women and men of reproductive potential who are unwilling or unable to use an effective means of birth control during the study and for  months after receiving study drug
Women of child-bearing potential must be willing to practice an effective method of birth control while on treatment
Men and women of childbearing potential must be willing to practice an effective method of birth control during treatment and for at least  months following treatment on study
Men who are able to father a child must agree to use an acceptable method of birth control while receiving radiation, and for  months after radiation
Patients of childbearing potential must agree to use an effective birth control method
Women of childbearing potential and men must agree to use a medically accepted form of birth control during the treatment and for  months following completion of study treatment
No patients who are pregnant or lactating will be allowed; patients of childbearing potential must practice an effective method of birth control while participating on this study
Women of childbearing potential and men must agree to use a medically accepted form of birth control for the duration of study participation and for  months following completion of study treatment
Women of child-bearing potential must be willing to practice an effective method of birth control while on treatment
Men and women of childbearing potential should practice  methods of contraception;  method must be highly effective and a second method must be either highly effective or less effective; men and women of childbearing potential are defined as: a male that has not been surgically sterilized or a female that has not been amenorrheic for at least  consecutive months or that has not been surgically sterilized; patients must use birth control during the study and for  months after the last dose of study drug if they are sexually active
Women of child-bearing potential must be willing to practice an effective method of birth control while on treatment
Women of childbearing potential must agree to practice effective birth control throughout their participation in the treatment phase of the study
Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months after completion of treatment
Female participants / women of childbearing potential (WOCBP) must adhere to using a medically accepted method of birth control up to  days prior to screening and agree to continue its use during the study or be surgically sterilized (e.g., hysterectomy or tubal ligation) and males must agree to use barrier methods of birth control while on study. WOCBP must agree to use effective contraception during treatment and for at least  months following the last dose of study treatment.
Women of child-bearing potential will practice a highly effective method of birth control during and for  months after the chemotherapy/ custirsen last dose. Men of reproductive potential who are not surgically sterile must agree to abstain from sexual activity or use medically accepted and highly effective method of contraception during and for  months after the chemotherapy/custirsen last dose.
All patients must practice a highly effective method of birth control
Men and women of reproductive potential who are unwilling to practice acceptable methods of effective birth control while on study through  weeks (women) or  months (men) after receiving the last dose of AMG ; acceptable methods of effective birth control include sexual abstinence (men, women); vasectomy; or a condom with spermicide (men) in combination with barrier methods, hormonal birth control or IUD (women)
Women of child-bearing potential must agree to use an effective method of birth control during treatment and for  months after receiving their last dose of study drug; fertile men must also agree to use an acceptable method of birth control while on study drug and for at least  months after last dose
Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control
Patients (men and women) of childbearing potential must agree to use double barrier method of birth control beginning at the signing of the informed consent form (ICF) until at least  months after the last dose of study drug
Women of childbearing potential and male participants must agree to use a medically effective means of birth control throughout their participation in the treatment phase of the study
Men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control
Men and women with reproductive potential: Must agree to use a reliable method of birth control during the study and for  months following the last dose of study drug(s) or country requirements, whichever is longer.
Patients of childbearing potential must agree to use an approved method of birth control
Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control
Patients (men and women) of child bearing potential should use an effective (for them) method of birth control throughout their participation in this study
Women of child-bearing potential must have a negative pregnancy test within  days of initiation of dosing and must agree to use an acceptable method of birth control while on study drug and for  months after the last dose; women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for >= year; men who are able to father a child must also agree to use an acceptable method of birth control while on study drug, and for  months after the last dose
All men and women of childbearing potential who are participating in the study must agree to use effective forms of birth control throughout the duration of their treatment
Females of childbearing potential must agree to use highly effective forms of birth control throughout the course of the study and at least up to  days after last dose of study drug. Males must have undergone sterilization- vasectomy, or utilize a barrier method
Men and women of reproductive potential who are unwilling to practice acceptable methods of effective birth control while on study through  weeks (women) or  months (men) after receiving the last dose of AMG ; acceptable methods of effective birth control include sexual abstinence (men, women); vasectomy; or a condom with spermicide (men) in combination with barrier methods, hormonal birth control or intrauterine device (IUD) (women)
Women of childbearing potential must agree to use highly effective methods of birth control.
Women of childbearing potential (WOCBP) must practice  effective methods of birth control during the course of the study; male patients who are partners of WOCBP should also practice an effective method of contraception; effective methods of birth control include diaphragm or condoms with spermicidal foam or jelly, birth control pills (BCPs), injections or patches, intra-uterine devices (IUDs) and surgical sterilization; postmenopausal women must be amenorrheic for >=  months to be considered of non-childbearing potential, women and men must continue birth control for the duration of the trial and >=  months after the last dose of study drug, All WOCBP MUST have a negative pregnancy test prior to beginning ibrutinib on study
Women of child-bearing potential are expected to use an effective method of birth control to prevent exposing a fetus to potentially dangerous agent with unknown risk
Women of child-bearing potential must have a negative pregnancy test within  days of initiation of dosing and must agree to use an acceptable method of birth control while on study drug and for  months after the last dose; women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for >=  year; men of child-bearing potential must also agree to use an acceptable method of birth control while on study drug, and for  months after the last dose
Women of childbearing potential and male participants must agree to use a medically effective means of birth control throughout their participation in the treatment phase of the study
Women of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to  months following treatment
Willingness to use effective means of birth control throughout the duration of clinical study and for at least  months after completion of study drug
Women of child-bearing potential must have a negative pregnancy test within  days of initiation of dosing and must agree to use an acceptable method of birth control while on study drug and for  months after the last dose. Women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for ? year. Men of child-bearing potential must also agree to use an acceptable method of birth control while on study drug, and for  months after the last dose.
Women of child-bearing potential must be willing to practice an effective method of birth control while on treatment
Women of child-bearing potential must agree to use an effective method of birth control during treatment and for six months after receiving their last dose of study drug
Inability or refusal to practice effective contraception during therapy or the presence of pregnancy or active breastfeeding (men and women of childbearing potential must use an effective method of birth control or abstinence during treatment and for  months after completion of treatment)
Non-pregnant and non-nursing; women and men of reproductive potential should agree to use an effective means of birth control
Men and women of child-bearing potential must be willing to practice an effective method of birth control during treatment and at least  months after treatment is finished
Men and women with reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment
Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin (HCG) within  hours prior to study entry and must be willing to practice effective birth control to prevent pregnancy while receiving treatment and for three months after treatment is discontinued; all males of child fathering potential must also be willing to practice effective birth control
Non-pregnant and non-nursing; women and men of reproductive potential should agree to use an effective means of birth control
Women of childbearing potential (WOCP) must have a negative pregnancy test result prior to enrollment. WOCP and men whose partners are WOCP must agree to use a highly effective method of birth control during the study and for  months following the last dose of study drug. A highly effective method of birth control is defined as one which results in a low failure rate (less than % per year).
Patients (men and women) of childbearing potential must use effective method of birth control throughout their participation in this study
Patients must not be pregnant; all premenopausal patients will undergo pregnancy testing; men will agree to not father a child while on protocol treatment; men and women will practice effective birth control while receiving protocol treatment
Women of childbearing potential and men must agree to use a medically accepted form of birth control for the duration of study participation and for  months following completion of study treatment
Pregnant and lactating women will be excluded; all premenopausal patients will undergo pregnancy testing; men will agree to not father a child while on protocol treatment; men and women will practice effective birth control while receiving protocol treatment
Women of child-bearing potential must have a negative pregnancy test within  days of initiation of dosing and must agree to use an acceptable method of birth control. Women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for ? year. Fertile men must also agree to use an acceptable method of birth control while on study drug and up to  months after the last dose of study drug.
Women of childbearing potential must agree to practice effective birth control throughout their participation in the treatment phase of the study
Woman of potential childbearing age agrees to a medically effective birth control method,
Women of child-bearing potential must have a negative pregnancy test within  days prior to initiation of dosing and must agree to use an acceptable method of birth control from the time of the negative pregnancy test up to  months after the last dose of study drug, Fertile men must also agree to use an acceptable method of birth control while on study drug and up to  months after the last dose of study drug.
All subjects of childbearing potential must agree to use acceptable methods of birth control (men and women)
Men and women of childbearing potential should practice effective methods of contraception; men and women of childbearing potential are defined as: a male that has not been surgically sterilized or female that has not been amenorrheic for at least  consecutive months or that has not been surgically sterilized; patients must use birth control during the study and for  months after the last dose of study drug if they are sexually active
Women of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to  months following treatment
Fertile men must agree to use an effective method of birth control during the study and for up to  months after the last dose of study drug.
Women of child-bearing potential must agree to use an effective method of birth control during treatment and for three months after receiving their last dose of study drug. Fertile men must also agree to use an acceptable method of birth control while on study drug and for at least  months after last dose.
Women of childbearing potential as well as fertile men and their partners must use an effective method of birth control
Not pregnant or breast feeding; women of childbearing potential and sexually active men must agree to use an accepted and effective method of birth control
Women of childbearing potential or men with partners of childbearing potential who are not protected or who are unwilling to use an effective contraceptive method of birth control during the course of the study and for a period of  months following the last dose.
Pregnant and/or lactating women will be excluded; all premenopausal patients will undergo pregnancy testing; men will agree to not father a child while on protocol treatment; men and women will practice effective birth control while receiving protocol treatment
Women of childbearing potential not using a highly effective method of birth control during the trial until one year after the last dose.
Men and woman of reproductive potential, unwilling to practice a highly effective method of birth control for the duration of the study and continuing for  weeks (for women) and  weeks (for men) after receiving the last dose of study drug.
Inability or refusal to practice effective contraception during therapy or the presence of pregnancy or active breastfeeding (men and women of childbearing potential must use an effective method of birth control or abstinence during treatment and for four months after completion of treatment)
Women and men agree to use protocol specific birth control measures
Women and men of reproductive potential must agree to use an effective means of birth control during the study and for  months after receiving study drug
Pregnant or breast feeding; women and men of reproductive potential must agree to use an effective means of birth control during the study and for  months after receiving study drug
Male and female subjects of reproductive potential who agree to use both a highly effective method of birth control and a barrier method during the period of therapy and for  days after the last dose of drug.
Women of childbearing potential are will to agree to use  of the study defined effective methods of birth control from the time of study entry to  days after the final study drug administration
For women of childbearing potential: unwillingness to use an effective method of birth control (e.g., abstinence, oral contraceptive) while in this study
Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control
Patients must agree to use an effective birth control method
Participant must be willing to use two effective forms of birth control during protocol therapy; men and women must continue using two effective forms of birth control for  months following treatment
Females of childbearing potential must use a highly effective method of birth control for at least  days before starting study, during participation and at least  days following last dose of sotatercept
Women of reproductive capability will be enrolled, but each woman needs to discuss with the study team the method of birth control used and if the method is a reliable and effective method for her; if a woman becomes pregnant during the course of active study participation, she must agree prior to enrolling in the study that she will report the pregnancy to the study team; with a confirmed pregnancy, the subject will no longer receive the assigned treatment, but will continue to be followed per protocol
Women and men must continue birth control for the duration of the trial and >=  months after the last dose of study drug
Women of child-bearing potential must be willing to practice an effective method of birth control while on study
Subjects who are of reproductive potential who refuse to use effective methods of birth control during the course of participation of the study and within  month for women and  months for men of the last dose of investigational agent are ineligible to participate in the study.
Patients must not be pregnant; all premenopausal patients will undergo pregnancy testing; men will agree to not father a child while on protocol treatment; men and women will practice effective birth control while receiving protocol treatment